Impact on Atrial Remodeling of Dapaglifozin in Patients With Heart Failure .

Dapagliflozin reduces the risk of de novo heart failure (HF) in diabetics and, recently, it has shown to improve the prognosis of patients with HF and reduced left ventricular ejection fraction (HFrEF), by preventing HF decompensations and cardiovascular death. The benefit showed by dapagliflozin in HFrEF was irrespective of diabetes status and glycemic control, which raises the question of which mechanisms are underlying apart from SGLT2 inhibition. In addition, the impact of dapagliflozin on cardiac remodeling parameters, as assessed by echocardiography and biomarkers, is not well established. In particular, left atrial (LA) remodeling represents a relevant prognostic marker, which has received a greater attention in the last years in the context of new imaging tools.

The purpose of this study is to assess the effect of dapagliflozin therapy over a period of 6 months in LA remodeling parameters, including geometry and function, as well as complementary biomarkers in patients with chronic HF regardless left ventricular ejection fraction (LVEF). This protocol will allow for evaluation of improved understanding of the interplay between dapagliflozin and LA function , biomarkers, remodeling and outcomes, and will carefully assess such relationships within important cohorts of subjects, such as those with reduced and preserved LVEF.

This protocol will also generate a biorepository of well-handled and carefully considered biomarkers, which will allow a better understanding of dapagliflozin mechanism of action.

The reduction of death and HF related events observed with dapagliflozin make necessary to clarify the mechanisms underlying these clinical benefits. Currently, dapagliflozin is indicated in patients with diabetes irrespective of the presence of HF. The initiation in patients with HF represents an opportunity to elucidate the effect of dapagliflozin on cardiac remodeling in this population. Therefore, we propose a study that aims to assess the effects of dapagliflozin in echocardiographic parameters of cardiac remodeling, with special interest in LA geometry and function, as well as in biomarkers reflecting expanded pathophysiological pathways. LA volume has shown to identify the progression of HF irrespective of LVEF and, therefore, it represents a meaningful measure of the cardiac impact of dapagliflozin in the entire spectrum of chronic HF.

Eligibility Criteria:
Inclusion Criteria:

* Age \> 18 years

  * Prior diagnosis of HF, with at least one hospitalization for HF at any time.
* NYHA class I-IV.
* LVEF available (echocardiogram or cardiac MRI) within the last 12 months prior to enrolment.
* Treatment according with contemporary guidelines recommendations and with stable doses of oral loop diuretics for at least 4 weeks
* NT-proBNP \>600 pg/ml at screening (≥400 pg/ml if hospitalized for HF within the previous 12 months; ≥900 pg/ml If concomitant AF at
* Screening irrespective of time to last HF hospitalization).

Exclusion Criteria:

* Dapagliflozin or other SGLT2i at any time in prior 6 months.
* Type 1 diabetes mellitus (T1D)
* Estimated glomerular filtration rate \< 30 ml/min/1.73 m2 as measured by the simplified Modification of Diet in Renal Disease (MDRD) formula at screening.
* Symptomatic hypotension or systolic blood pressure (SBP) \<95 mmHg on 2 consecutive measurements at screening.
* Uncontrolled hypertension, defined as SBP \>160 mmHg.
* Current acute decompensated HF or hospitalization due to decompensated HF within 4 weeks prior to enrolment
* The use of outpatient or inpatient i.v. diuretic therapy within 4 weeks prior to baseline.
* Subjects who are currently receiving or have received inotropic agents within 12 weeks prior to baseline.
* Myocardial infarction, unstable angina, stroke or transient ischemic attack within 12 weeks prior to enrolment
* Coronary revascularization (percutaneous coronary intervention or coronary artery bypass grafting or valvular repair/replacement within 12 weeks prior to enrolment or planned to undergo any of these operations after inclusion
* Implantation of a cardiac resynchronization therapy (CRT) within 12 weeks prior to enrolment or intent to implant a CRT device
* Previous cardiac transplantation or implantation of a ventricular assistance device (VAD) or similar device, or implantation expected after inclusion
* HF due to restrictive cardiomyopathy, active myocarditis, constrictive pericarditis, hypertrophic (obstructive) cardiomyopathy or uncorrected primary valvular disease
* Symptomatic bradycardia or second or third degree heart block without a pacemaker
* History of allergic reactions or intolerance to dapagliflozin, or other iSGLT2, or any other compound
* History of malignancy of any organ system (other than localized basal cell carcinoma of the skin), treated or untreated, within one year.
* Hepatic impairment aspartate transaminase \[AST\] or alanine transaminase \[ALT\] \>3x the upper limit of normal \[ULN\]; or total bilirubin \>2x ULN at time of screening)
* Women of child-bearing potential (ie, those who are not chemically or surgically sterilised or who are not post-menopausal) who are not willing to use a medically accepted method of contraception that is considered reliable in the judgment of the investigator or women who have a positive pregnancy test at enrollment or randomization or women who are breast-feeding
* Participation in another clinical trial during the last month prior to enrolment
* Inability of the patient, in the opinion of the investigator, to understand and/or comply with study medications, procedures and/or follow-up or any conditions that, in the opinion of the investigator, may render the patient unable to complete the study
* Any concomitant disease limiting life expectancy in the following year (other than heart failure)
* No possibility to give informed consent.